The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XXVII.b

Esophageal toxicity

Publications

Pan Y, Brink C, Knap M, Khalil AA, Nyhus CH, McCulloch T, Holm B, Wu YL, Schytte T, Hansen O

Acute esophagitis for patients with local-regional advanced non small cell lung cancer treated with concurrent chemoradiotherapy.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2016;118(3):465-70

Stephans KL, Djemil T, Diaconu C, Reddy CA, Xia P, Woody NM, Greskovich J, Makkar V, Videtic GM

Esophageal dose tolerance to hypofractionated stereotactic body radiation therapy: risk factors for late toxicity.

International journal of radiation oncology, biology, physics. 2014;90(1):197-202

Sainathan S, Wu LD, Andaz S

Delayed esophageal perforation from stereotactic body radiation therapy for locally recurrent central nonsmall cell lung cancer.

Lung India : official organ of Indian Chest Society. 2014;31(2):158-60

Palma DA, Senan S, Oberije C, Belderbos J, de Dios NR, Bradley JD, Barriger RB, Moreno-Jiménez M, Kim TH, Ramella S, Everitt S, Rengan R, Marks LB, De Ruyck K, Warner A, Rodrigues G

Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: an individual patient data meta-analysis.

International journal of radiation oncology, biology, physics. 2013;87(4):690-6